Literature DB >> 21262917

Prognostic significance of p14ARF, p15INK4b, and p16INK4a inactivation in malignant peripheral nerve sheath tumors.

Makoto Endo1, Chikashi Kobayashi, Nokitaka Setsu, Yusuke Takahashi, Kenichi Kohashi, Hidetaka Yamamoto, Sadafumi Tamiya, Shuichi Matsuda, Yukihide Iwamoto, Masazumi Tsuneyoshi, Yoshinao Oda.   

Abstract

PURPOSE: p14(ARF), p15(INK4b), and p16(INK4a) are tumor suppressor genes that are located closely at 9p21 and are often coinactivated by genetic or epigenetic alterations. Malignant peripheral nerve sheath tumor (MPNST) is a rare sarcoma with poor prognosis. However, the prognostic implications of inactivation of p14(ARF), p15(INK4b), and p16(INK4a) in MPNSTs have not been adequately investigated. Here we carried out a genetic, epigenetic, and expression analysis of p14(ARF), p15(INK4b), and p16(INK4a), and clarified the prognostic significance of their inactivation in MPNSTs. EXPERIMENTAL
DESIGN: p14(ARF), p15(INK4b), and p16(INK4a) protein expressions were assessed by immunohistochemistry in 129 formalin-fixed samples of MPNST including 85 primary tumors. Thirty-nine samples, for which frozen material was available, were also investigated by Western blotting and quantitative reverse transcription PCR (RT-PCR) to detect p14(ARF), p15(INK4b), and p16(INK4a) protein and mRNA expression, and by multiplex real-time PCR, PCR single strand conformation polymorphism and methylation-specific PCR to detect p14(ARF), p15(INK4b), and p16(INK4a) gene alterations.
RESULTS: Immunohistochemically decreased expressions of p14(ARF), p15(INK4b), and p16(INK4a) were observed in 48%, 54%, and 49% of primary MPNSTs, respectively, and were significantly correlated with their concordant mRNA levels. As for gene alterations, homozygous deletion of CDKN2A was detected in one third of the cases. Inactivation of p14(ARF) and p16(INK4a) was associated with poor prognosis by both univariate and multivariate analyses. Furthermore, cases with inactivation of all p14(ARF), p15(INK4b), and p16(INK4a) genes showed the worst prognosis in a combined prognostic assessment.
CONCLUSION: A comprehensive analysis of p14(ARF), p15(INK4b), and p16(INK4a) inactivation status provides useful prognostic information in MPNSTs. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21262917     DOI: 10.1158/1078-0432.CCR-10-2393

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  27 in total

1.  Genomic and molecular characterization of malignant peripheral nerve sheath tumor identifies the IGF1R pathway as a primary target for treatment.

Authors:  Jilong Yang; Antti Ylipää; Yan Sun; Hong Zheng; Kexin Chen; Matti Nykter; Jonathan Trent; Nancy Ratner; Dina C Lev; Wei Zhang
Journal:  Clin Cancer Res       Date:  2011-10-31       Impact factor: 12.531

Review 2.  Diagnosis and Management of Subcutaneous Soft Tissue Sarcoma.

Authors:  Makoto Endo; Nokitaka Setsu; Toshifumi Fujiwara; Takeaki Ishii; Makoto Nakagawa; Kenichiro Yahiro; Atsushi Kimura; Eijiro Shimada; Yasuharu Nakashima; Yoshihiro Matsumoto
Journal:  Curr Treat Options Oncol       Date:  2019-05-25

3.  Morphologic and immunohistochemical features of malignant peripheral nerve sheath tumors and cellular schwannomas.

Authors:  Melike Pekmezci; David E Reuss; Angela C Hirbe; Sonika Dahiya; David H Gutmann; Andreas von Deimling; Andrew E Horvai; Arie Perry
Journal:  Mod Pathol       Date:  2014-09-05       Impact factor: 7.842

4.  Transgenic mice overexpressing neuregulin-1 model neurofibroma-malignant peripheral nerve sheath tumor progression and implicate specific chromosomal copy number variations in tumorigenesis.

Authors:  Syed J Kazmi; Stephanie J Byer; Jenell M Eckert; Amy N Turk; Richard P H Huijbregts; Nicole M Brossier; William E Grizzle; Fady M Mikhail; Kevin A Roth; Steven L Carroll
Journal:  Am J Pathol       Date:  2013-01-13       Impact factor: 4.307

5.  Malignant peripheral nerve sheath tumors presenting as spinal dumbbell tumors: clinical outcomes and characteristic imaging features.

Authors:  Yoshihiro Matsumoto; Makoto Endo; Katsumi Harimaya; Mitsumasa Hayashida; Toshio Doi; Yukihide Iwamoto
Journal:  Eur Spine J       Date:  2015-10       Impact factor: 3.134

6.  North American ATLL has a distinct mutational and transcriptional profile and responds to epigenetic therapies.

Authors:  Urvi A Shah; Elaine Y Chung; Orsi Giricz; Kith Pradhan; Keisuke Kataoka; Shanisha Gordon-Mitchell; Tushar D Bhagat; Yun Mai; Yongqiang Wei; Elise Ishida; Gaurav S Choudhary; Ancy Joseph; Ronald Rice; Nadege Gitego; Crystall Parrish; Matthias Bartenstein; Swati Goel; Ioannis Mantzaris; Aditi Shastri; Olga Derman; Adam Binder; Kira Gritsman; Noah Kornblum; Ira Braunschweig; Chirag Bhagat; Jeff Hall; Armin Graber; Lee Ratner; Yanhua Wang; Seishi Ogawa; Amit Verma; B Hilda Ye; Murali Janakiram
Journal:  Blood       Date:  2018-08-13       Impact factor: 22.113

7.  BET bromodomain inhibition triggers apoptosis of NF1-associated malignant peripheral nerve sheath tumors through Bim induction.

Authors:  Amish J Patel; Chung-Ping Liao; Zhiguo Chen; Chiachi Liu; Yong Wang; Lu Q Le
Journal:  Cell Rep       Date:  2013-12-27       Impact factor: 9.423

8.  Expression of p15INK⁴b and p57KIP² and relationship with clinicopathological features and prognosis in patients with vulvar squamous cell carcinoma.

Authors:  Ruth Holm; Mette Førsund; Mai T Nguyen; Jahn M Nesland; Claes G Trope
Journal:  PLoS One       Date:  2013-04-08       Impact factor: 3.240

9.  Prognostic impact of Jab1, p16, p21, p62, Ki67 and Skp2 in soft tissue sarcomas.

Authors:  Sveinung W Sorbye; Thomas K Kilvaer; Andrej Valkov; Tom Donnem; Eivind Smeland; Khalid Al-Shibli; Roy M Bremnes; Lill-Tove Busund
Journal:  PLoS One       Date:  2012-10-05       Impact factor: 3.240

10.  Humanized neurofibroma model from induced pluripotent stem cells delineates tumor pathogenesis and developmental origins.

Authors:  Juan Mo; Corina Anastasaki; Zhiguo Chen; Tracey Shipman; Jason Papke; Kevin Yin; David H Gutmann; Lu Q Le
Journal:  J Clin Invest       Date:  2021-01-04       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.